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Background: the World Health Organization recommends hospitalization 
and injectable antibiotic treatment for young infants (0–59 days old), who 
present with signs of possible serious bacterial infection. Fast breathing 
alone is not associated with a high mortality risk for young infants and has 
been treated with oral antibiotics in some settings. this trial was designed 
to examine the safety and efficacy of oral amoxicillin for young infants with 
fast breathing compared with that of an injectable penicillin–gentamicin 
combination. the study is currently being conducted in the Democratic 
Republic of Congo, Kenya and nigeria.
Methods/Design: this is a randomized, open-label equivalence trial. All 
births in the community are visited at home by trained community health 
workers to identify sick infants who are then referred to a trial study nurse for 
assessment. the primary outcome is treatment failure by day 8 after enroll-
ment, defined as clinical deterioration, development of a serious adverse event 
including death, persistence of fast breathing by day 4 or recurrence up to 
day 8. Secondary outcomes include adherence to study therapy, relapse, death 
between days 9 and 15 and adverse effects associated with the study drugs. 
Study outcomes are assessed on days 4, 8, 11 and 15 after randomization by 
an independent outcome assessor who is blinded to the treatment being given.
Discussion: the results of this study will help inform the development 
of policies for the treatment of fast breathing among neonates and young 
infants in resource-limited settings.
Key Words: neonates, young infants, antibiotic treatment, fast breathing, 
severe infection
(Pediatr Infect Dis J 2013;32:S33–S39)
Neonatal sepsis, meningitis and pneumonia are major causes of morbidity and mortality in developing countries, resulting in 
an estimated 700,000–800,000 deaths per year.1 As it is clinically 
difficult to differentiate between these infections, they are often 
identified together as a clinical syndrome of possible serious bacte-
rial infection (pSBI). Signs used to diagnose this syndrome include 
poor feeding, convulsions, fast breathing, severe chest indrawing, 
fever or hypothermia and movement only when stimulated or no 
movement at all.2 the World Health Organization (WHO) cur-
rently recommends transfer to a referral facility, hospitalization and 
injectable antibiotic therapy with a combination of gentamicin and 
penicillin/ampicillin for 7-10 days for the management of this clini-
cal syndrome in young infants up to 2 months of age.2,3
Concerns have been raised about these recommendations. 
First, many infants experiencing pSBI are not referred for hospi-
tal care, either due to limited access or refusal on the part of fam-
ilies.4–7 Second, while fast breathing is the most common clinical 
sign suggesting pneumonia or sepsis among children with pSBI, 
it is less severe than the other signs included in the syndrome. A 
multicountry study reported that fast breathing was seen in up 
to one-fifth of sick young infants presenting to a health facility.8 
Furthermore, fast breathing was not predictive of mortality in 
studies from Bangladesh and India, unlike other more serious 
signs such as lethargy or unconsciousness, convulsions, inability 
to breastfeed well, hypothermia and chest indrawing.9–11
In some settings, neonates and young infants with fast breath-
ing have been successfully managed with oral antibiotics in the com-
munity, resulting in low case fatality rates and reductions in neonatal 
and infant mortality.12–14 However, these studies were all conducted in 
Asia and none compared oral antibiotic treatment with the standard 
therapy of penicillin and gentamicin injections. therefore, to better 
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inform public health policy for the management of fast breathing, 
there is a need to evaluate whether young infants with fast breathing 
alone can be safely and effectively treated in the community with oral 
antibiotics alone, particularly in previously unstudied African settings.
In 2009, WHO requested proposals from African sites inter-
ested in conducting a randomized, open-label equivalence trial to 
address this issue. After an external review process, 5 sites in Africa 
were selected to participate in this study using a common protocol. 
the sites include 1 site each in the Democratic Republic of Congo 
(DRC) and Kenya, and 3 sites in nigeria (Ibadan, Ile-Ife and Zaria). 
this article describes the protocol for this trial.
OBJECTIVES
the overall goal of the study was to inform policy on 
the use of oral amoxicillin for young infants with fast breath-
ing. Our underlying hypothesis is that young infants with “fast 
breathing” alone can be safely and effectively managed with an 
oral antibiotic.
•  primary objective: to evaluate the use of oral amoxicillin com-
pared with intramuscular procaine penicillin and gentamicin for 
the provision of safe and effective treatment at first-level facili-
ties and in the community for 0- to 59-day-old young infants 
with fast breathing alone, whose families do not accept or cannot 
access referral level care.
•  Secondary objectives: to assess family acceptance of and com-
pliance with an oral antibiotic treatment regimen compared with 
intramuscular antibiotic injections and to document and compare 
the health worker time costs and other logistical requirements of 
the 2 treatment regimens.
METHODS
Study Settings
this study is being carried out at 5 sites, 1 each in DRC 
and Kenya and 3 sites in nigeria; Ibadan, Ile-Ife and Zaria. Of 
note, another study is being performed concomitantly in the same 
study sites for young infants with clinical severe infection (one or 
more of the following 5 signs: poor feeding, movement only when 
stimulated, severe chest indrawing, axillary temperature >38.0°C 
or <35.5°C), who are treated with different experimental antibiotic 
regimens, although the reference treatment arm is the same for both 
studies. As some components of the methods are common for both 
studies, we have reported the commonalities such as the description 
of study sites and details of data management only in the clinical 
severe infection methods paper, also published in this supplement.15
Study Design
the study approach is outlined in Figure 1. this is an indi-
vidually randomized, open-label equivalence trial. All 5 study sites 
will contribute to the overall sample size. Sites in the DRC, Kenya 
and nigeria are following the same study design, with similar inclu-
sion criteria, the same intervention, comparison and outcomes, as 
well as quality control and coordination mechanisms.
Participants
Identification of Newborns
Births are identified by community health workers (CHWs), 
community health extension workers (CHeWs) and traditional birth 
attendants and are reported within 24 hours of delivery. CHWs and 
traditional birth attendants cannot give injections; in contrast, CHeWs 
(only present in nigeria) receive 2 years of professional training and 
thus can give injections. In the DRC, birth information is also transmit-
ted by health center nurses directly to the study enrollment/treatment 
nurse or the study community coordinator. CHWs/CHeWs transmit 
information to the community coordinator/supervisor/cluster coordi-
nator as soon as possible. the CHWs/CHeWs record details of the 
household and the place where the birth occurred; they also perform 
a postnatal home visit on the day of birth (day 1) and on days 3, 7, 14, 
21, 28, 35, 42, 49 and 60 to check the newborn’s condition. CHWs/
CHeWs provide families with contact details and counsel parents on 
the need to report any concerns they have about their newborn. the 
CHWs/CHeWs alert an enrollment nurse if there are any young infants 
with fast breathing or other symptoms and signs suggestive of pSBI 
whose parents refuse referral. In DRC and Kenya, the CHW accom-
panies the family to the health center if the family agrees, whereas in 
nigeria the study enrollment/treatment nurse is called to infant’s home.
Screening and Enrollment
Screening and enrollment are conducted by enrollment/treat-
ment nurses. In DRC and Kenya, this takes place at the health center/
dispensary. In the nigerian sites, it takes place at the child’s home. 
All young infants with suspected pSBI are referred by the enrollment 
nurse. Infants with pSBI whose parents/caretakers refuse referral for 
treatment are evaluated for inclusion/exclusion criteria and if found 
eligible, the study is explained to the parents. the mother/caregiver 
is counseled on the implications of refusing referral. If the parents 
agree to participate in the study, consent is obtained from the mother/
father. If he/she is illiterate, she/he will affix a thumbprint on the 
form in the presence of a literate witness who signs the same form.
Young infants are included in the study if they fulfill the fol-
lowing criteria:
• Age 0–59 days of age.
•  Fast breathing, defined as respiratory rate of >60 breaths per 
minute.
• Do not have any of the following exclusion criteria:
○  Signs of severe infection (defined as poor feeding on 
observation, movement only when stimulated, severe chest 
indrawing and axillary temperature ≥38.0°C or <35.5°C);
○  Critically ill (characterized by the presence of any of the fol-
lowing signs: unconsciousness, convulsions, unable to feed 
at all, apnea, unable to cry, cyanosis, dehydration, bulging 
fontanel, major congenital malformations inhibiting oral 
antibiotic intake, active bleeding requiring transfusion, 
surgical conditions needing hospital referral and persistent 
vomiting defined as vomiting following 3 attempts to feed 
the baby within one-half hour);
○ Very low weight (<1500 g at the time of presentation);
○  Hospitalized for illness in the last 2 weeks or previously 
enrolled in the study.
• parents do not accept or cannot access referral level care.
• parents give consent to participate in the study.
At the time of enrollment, infants are stratified into 2 age 
groups: 0–6 days and 7–59 days. they are individually randomized 
to treatment regimens within each site and age stratum. the refer-
ence treatment is injectable gentamicin once daily and injectable 
procaine penicillin once daily for 7 days (treatment regimen A). 
the intervention arm consists of oral amoxicillin twice daily for 7 
days (dosages described below).
Randomization schemes with a block size of 8 were com-
puter-generated off-site at WHO using StAtA version 10.0 (StAtA 
Corp., College Station, tX) by a person not involved with the study. 
For allocation concealment, treatment codes are printed on small 
pieces of card folded once and sealed in an opaque envelope (2 sets 
of color-coded envelopes are used, one for each age group).
treatments are given at a health facility or at home. Injec-
tions are given once daily by a health worker at a facility or at 
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home, whereas oral medicines are given at home by the mother 
under the supervision of CHWs. A daily assessment by a health 
worker (treatment nurses in DRC and Kenya and CHeW in 
nigeria) is conducted to identify possible treatment failures.
Allocation of Treatment Arm
In the Kenyan and nigerian sites, the randomization list is 
held centrally and the treatment allocation is provided to the enroll-
ment nurse, according to the child’s age category, by phone and is 
confirmed by SmS. In the DRC where mobile phone communica-
tion is generally unavailable across the study catchment area, each 
facility where enrollment occurs is given a block of 8 envelopes 
for each age group, and used blocks are regularly replaced so that 
a sufficient number of envelopes are always available at the facility. 
When the first young infant is enrolled at a facility in a stratum, the 
first envelope of the block for that stratum and age category at the 
facility is opened and the infant is treated according to the treatment 
code inside. When the next infant is enrolled, the next envelope of 
Treatment at health facility (or at home)
 Treatment for 7 days according to randomization code 
 Injections given once daily by Health Worker at facility or at home 
 Oral medicines given by mother under supervision of HW/CHW 
 Daily assessment by Health Worker providing treatment to detect worsening 
Community-based surveillance for neonatal illness
Follow up of pregnancies, identification of births by CHWs/TBAs: 
Home visits by CHWs to identify ‘danger signs’* on Day 1, 3, 7, 14, 21, 28, 35, 42, 49, 60
Management of illness by a professional Health Worker (nurse or clinical officer) 
Sick young infant taken to health facility by CHW (or visited by Health Worker at home) 
Examined for signs of ‘Possible Serious Bacterial Infection’ by Health Worker 
Hospital referral recommended and assisted if these signs present 
Screening
If the family does not 
accept referral, the young 
infant is classified as: 
If family accepts referral, 
follow up* 
Critically ill 
(see definition in text)  
and 
Clinical severe infection  
(Feeding poorly, moves 
only on stimulation, severe 
chest indrawing, 
temperature <35.5oC
or >38oC
Fast breathing only
Informed consent to
participate in study by 
the family 
Enrollment and randomization
by age groups  
<7 days and 7-59 days  
(colour coded envelopes) 
Independent Outcome assessment
Outcome assessment by independent assessor (experienced nurse or physician) 
Scheduled outcome assessment at Day 4, 8, 11 and 15 of enrolment 
Additionally, confirmation of worsening when detected by treating health workers 
*Only if families provide consent for this follow-up visit to document outcome
Excluded from study 
FIGURE 1. Overall study approach.
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the appropriate stratum and age category block is opened. A record 
of all randomizations is kept by the study supervisors or study com-
munity coordinators.
Provision of Treatment
In the DRC and Kenya, all injectable treatment is provided at 
the health facility, by the enrollment/treatment nurse who also pro-
vides the first dose of oral therapy. mothers observe the first dose being 
given and are instructed on provision of oral amoxicillin at home. In 
nigeria, the first dose of injectable and of oral treatment is provided at 
home by the enrollment/treatment nurse after randomization. the rest 
of the injectable treatments are provided by CHeWs. Oral treatments 
are given to the mother of the enrolled infant and are administered in 
the home, under direct observation of the CHW/CHeW.
Outcome Assessment of Enrolled Patients
An independent outcome assessment nurse visits enrolled 
infants on days 4, 8, 11 and 15 after the day of enrollment to assess 
outcome. All assessments are conducted at the young infant’s home.
Choice of Antibiotic Regimens
A combination of penicillin and gentamicin injections is 
currently the WHO recommended treatment for pSBI in young 
infants. thus, single daily injections of procaine penicillin and gen-
tamicin were chosen as the reference treatment. A detailed rationale 
for the selection of antibiotics and study outcomes is described in 
another article in this supplement.16
Oral amoxicillin has been shown to be superior to oral tri-
methoprim-sulfamethoxazole for the treatment of pneumonia17,18 and 
has been shown to be effective in treating severe pneumonia in chil-
dren 2–59 months of age.19–22 the most frequent pathogens associated 
with pneumonia are generally similar in neonates and young children 
and are frequently susceptible to amoxicillin.17,23 Oral amoxicillin 
was therefore chosen as the experimental treatment for this study.
the antibiotic dosages for young infants enrolled in the 
study are injection procaine penicillin in a dose of 50,000 units/kg 
once-daily Im; injection gentamicin in the range 4.0–7.5 mg/kg/d 
once-daily dose Im (depending on age of the young infant) and oral 
amoxicillin in suspension form in a dose of 100 mg/kg/d (<2 kg are 
given 75 mg/kg/d), divided in 2 equal doses. Both treatment regi-
mens are being used for 7 days.
Study Outcomes
Primary Outcome
the primary outcome for the study is treatment failure by 
the day 8 postenrollment visit. treatment failure is defined as any 
one of the following:
 • Death;
 • Clinical deterioration, defined as the emergence of any sign of 
severe infection or critical illness at any time after enrollment 
(as defined in exclusion criteria), or hospitalization any time 
after enrollment;
 • persistence of fast breathing on day 4 or recurrence after day 
4 up to day 8;
 • Development of a serious adverse event (other than death) that 
is related to the study antibiotics, eg, organ failure, anaphy-
lactic reaction, severe diarrhea, disseminated and severe rash;
Secondary Outcomes
 • Death occurring 9–15 days after enrollment;
 • Relapse, defined as fast breathing that disappears on day 8 of 
enrollment and reemerges between days 9 and 15, or develop-
ment of any sign of severe infection or critical illness signs 
between days 9 and 15 after enrollment;
 • Adherence to the study therapy between days 1 and 8.
Sample Size
In the absence of population-based incidence data, the inci-
dence of fast breathing was conservatively estimated to be about 
3.5% in Africa. the figure is based on a large multicenter study, 
where 5–18% of all sick young infants brought for care had fast 
breathing.8 Community-based studies in India and Bangladesh 
reported that 4.6–8.1% of babies had fast breathing at some point 
during the neonatal period.4,24
the sample size calculations assumed that the statistical 
analysis will be based on a comparison between the failure rate 
observed with the reference treatment regimen of injection penicil-
lin and gentamicin for 7 days (assumed treatment failure rate of 
8%) and the experimental regimen of oral amoxicillin for 7 days. 
A point estimate of the failure rate difference (experimental—ref-
erence treatment) between the 2 treatment regimens will be calcu-
lated together with a 2-sided 95% confidence interval. the alterna-
tive treatment will be judged to be “of similar effectiveness” to the 
reference treatment if the upper bound of the 95% confidence inter-
val lies below the allowed “similarity margin” of +4%. A power of 
90% to demonstrate the similarity of 2 treatments over the 7-day 
period following randomization was required, assuming that the 
true failure rates with the reference treatment and the experimental 
treatment regimens will be identical (assumed to be 8%).
using the above assumptions, the required sample size was 
determined to be 1150 infants for each treatment group, which is 
likely to yield 970 “analyzable” infants per treatment arm.
Data Collection, Management and Analysis
Data are collected either at home or in the health facility on 
paper-based standard case report forms; forms are completed by 
CHWs/CHeWs, enrollment and treatment nurses, and independent 
outcome assessors. All completed case report forms are checked by 
study supervisors before the data entry. Data are entered into a Struc-
tured Query language database specifically developed for the study. 
Double data entry is carried out by data entry clerks at each site; logi-
cal checks are performed by the data manager in consultation with the 
study supervisor and if necessary by the principal investigator. the 
cleaned database is sent monthly to the central data coordination center 
at the london School of Hygiene and tropical medicine (lSHtm), 
which developed the data management system. Quality checks are 
carried out both at the site and at lSHtm. lSHtm assists in quality 
control through database monitoring and preparing necessary reports 
for the Data Safety monitoring Board (DSmB) and the trial technical 
Advisory Group (tAG); they also liaise with the WHO study coordi-
nation team. Further details are described in the accompanying article 
on severe infections, as the trials were conducted concurrently.15
Analysis Plan
the primary analysis will be a combined analysis across all 
the sites. Simple comparisons of means and proportions by treat-
ment group will be used to check whether the randomization scheme 
resulted in baseline comparability of the treatment groups. the primary 
analyses will be for equivalence between the reference treatment and 
the experimental (intervention) arm. It will consist of the comparison 
of proportions of infants with treatment failure in each treatment arm.
the primary analysis will be conducted on a per-protocol basis; 
an intention-to-treat analysis will also be conducted. For an enrolled 
infant to be included in the per-protocol analysis, she/he should have 
received: (1) all antibiotic doses due to be received for the first 3 days 
of treatment or by the time of treatment failure; and (2) at least 50% 
of all scheduled doses of each antibiotic on days 4–7 or by the time 
of treatment failure. Furthermore, for inclusion in the per-protocol 
analysis, follow-up must be completed on assessment days 2–4 and 
on at least 1 of days 5–8, and vital status on day 8 must be known.
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Analyses will be performed with data from all sites, adjusted 
for any baseline covariates that were unbalanced at baseline and 
with addition of dummy variables for site and age group. the pri-
mary and secondary outcomes, the proportion of young infants who 
received treatment for the entire duration and costs of such treat-
ment will be compared across the 2 study arms. the difference in the 
risk of treatment failure together with 95% confidence intervals will 
be calculated. Secondary analyses will be performed to investigate 
the effect on adverse events including death and other serious out-
comes such as diarrhea with severe dehydration, disseminated and 
severe rash, anaphylactic reaction, stopped passing urine for >12 
hours, cellulitis or abscess at injection site. univariate and multivari-
ate regression analyses will be undertaken to identify predictors of 
treatment failure for young infants with fast breathing.
Ethical Issues
Study Approvals
the trial protocol and all associated data collection instru-
ments and consent forms were submitted for ethical review to the 
local institutional review boards at each site as well as to the WHO 
ethical Review Committee and to lSHtm. the trial was registered 
as ACtRn12610000286044 with Australian new Zealand Clini-
cal trials Registry. the trial follows the Council for International 
Organizations of medical Sciences (CIOmS) and Good Clinical 
practice guidelines.
Informed Consent
the study was explained to members of the community at all 
sites before study enrollment; this was achieved through meetings 
with community leaders and community groups. Informed writ-
ten consent is obtained for the home visits for pregnancy and birth, 
enrollment and treatment, as well as for the follow-up visit of the 
nonenrolled infants. Safety of young infants enrolled in this trial was 
ensured by close monitoring and follow-up. Health workers were 
trained to facilitate referral through counseling using integrated 
management of childhood illness guidance for assisting referral. 
Only babies whose families refused referral and were willing to 
document this by witnessed signature/thumbprint were enrolled.
Monitoring of Potential Adverse Events
the families are asked to contact the CHW/CHeW if any 
adverse events occur (as defined in the study protocol). In the case of 
an adverse event, CHWs contact the supervising CHW and CHeWs 
call the outcome assessment nurse, who then confirms and docu-
ments the adverse event and conveys the information to the com-
munity coordinator/supervisor. All serious adverse events (includ-
ing death, unable to pass urine for >12 hours, anaphylactic reaction, 
severe dehydration due to diarrhea, disseminated or severe rash) are 
reported to WHO within 48 hours of occurrence. this information 
is also provided on a regular basis to DSmB, institutional review 
boards and the WHO ethical Review Committee.
Rescue Therapy
Should the condition of the infant worsen and he/she 
requires further medical care, the infant may be given rescue ther-
apy as determined by the study protocol. this includes intramus-
cular ceftriaxone for 7 days if the families still refuse referral to a 
higher level of care.
Data Safety Monitoring Board
the DSmB is responsible for monitoring and assessing the 
safety of the trial and consists of an epidemiologist, a statistician 
and a clinician scientist/researcher from each of the 3 countries. 
the DSmB convenes at least once a year in a face-to-face meeting, 
which consists of both an open and a closed session. two interim 
analyses will be conducted, first when one-third of participants and 
second when two-thirds of the participants have been enrolled and 
treated. the interim analysis is conducted on a blinded basis.
the DSmB recommended that the trial be stopped or modi-
fied if an interim analysis of the safety endpoints of neonatal deaths 
and/or serious adverse events demonstrated a difference between 
treatment and control of at least 2 standard errors (P = 0.01) for 
effectiveness or futility. Furthermore, termination or modifica-
tion may be recommended for any other perceived safety concern 
based on clinical judgment, including but not limited to a higher 
than anticipated rate for any component of the primary endpoint 
or unexpected serious adverse events. For this purpose, the serious 
adverse event forms are sent to the DSmB on the quarterly basis.
Quality Assurance
Training
training courses were held for master trainers from all sites; 
these master trainers then trained local study personnel. training 
covered the following courses: WHO/unICeF Home Care for 
newborns, WHO/unICeF Young Infant integrated management of 
childhood illness (for study nurses) and a study-specific procedures 
course. All CHWs/CHeWs and enrollment, treatment and outcome 
assessment nurses employed by the study were trained at their 
respective sites by the master trainers. All supervisors and site coor-
dinators were also trained in all courses. Further details of training 
are given in the accompanying methods paper on severe infection.15
Standardization, Quality Assurance of Training and 
Quality Control
Before starting study enrollment, standardization exercises 
are conducted on clinical and other study procedures for the appro-
priate cadres of workers, including CHW/CHeWs, enrollment and 
treatment nurses, independent outcome assessors, supervisors and 
study coordinators. Standardization exercises are repeated every 6 
months over the course of the study. Data-based monitoring is also 
carried out with the help of the DmC in london and the WHO 
coordination team in Geneva. Further details on quality assurance 
are given in the accompanying articles.15,25
Supervision
Supervisors make accompanied and unaccompanied visits 
regularly to oversee field activities. Investigators made random vis-
its to check quality.
Site Monitoring
All sites prepare and submit monthly progress reports, 
which are reviewed by the WHO coordination team on a monthly 
basis. Regular conference calls are held to review progress. WHO 
monitors conduct site visits twice a year to review progress in the 
field. Further details on site monitoring are given in the accompa-
nying methods paper.15
Coordination Mechanisms
the WHO Department of maternal, newborn, Child and 
Adolescent Health is coordinating this study. technical advice is 
provided by a tAG, which includes all principal investigators, the 
WHO coordination team and external experts. the tAG convenes at 
least once a year in a face-to-face meeting. lSHtm assists in qual-
ity control through database monitoring and preparation of reports 
for the DSmB, the tAG and the WHO study coordination team.
Timelines
the enrollment of the study participants started in April 
2011 at all study sites and is likely to be complete by may 2013.
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DISCUSSION
the current WHO algorithm for identification of pSBI in young 
infants includes a range of signs from milder signs such as fast breath-
ing to very serious signs like convulsions and no movement on stimu-
lation. WHO recommends that sick infants with any of these signs be 
referred for hospitalization and treated with up to 50 injections with a 
penicillin (benzyl penicillin or ampicillin) plus gentamicin for at least 10 
days. this is not always feasible for a variety of reasons, including fami-
lies’ lack of access to appropriate health facilities and the cost of such 
treatment. Young infants with fast breathing are at lower risk of serious 
adverse events compared with sick young infants with other more seri-
ous signs.10,11 evidence also suggests that fast breathing in young infants 
can be treated with oral antibiotics in the community.13 moreover, the 
safety, feasibility and cost of managing severe neonatal infections in 
community settings to address high neonatal mortality have been identi-
fied as a high research priority.26 If this study demonstrates that young 
infants with fast breathing can be treated safely and effectively with oral 
amoxicillin at home, it would greatly benefit both the families and health 
system and would facilitate increased coverage of treatment.
Blinding of therapy was not possible in this trial because 
of the differences in delivery of the 2 experimental regimens. 
Although the assessment of treatment failure is to some degree 
subjective, based on the presence or absence of clinical signs, an 
independent outcome assessor who is blinded to the treatment regi-
men assesses the study outcomes.
the ongoing trial described in this article is a multicenter, 
multicountry study involving 5 sites. the primary health care sys-
tem is operational in all study areas, but referral systems are weak 
or unavailable in most of the study areas. this study is the largest 
community-based study evaluating a simplified antibiotic regimen 
for fast breathing in neonates and young infants in Africa and will 
provide important information to help formulate local and global 
policies to better manage pSBI in young infants.
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